These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18794453)

  • 1. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
    Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
    Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.
    Majhail NS; Schiffer CA; Weisdorf DJ
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):789-91. PubMed ID: 16785069
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
    Martínez C
    Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():69-71. PubMed ID: 21381292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A call for more dermatologic input into chronic graft-vs-host disease clinical trials.
    Cowen EW
    Arch Dermatol; 2009 Mar; 145(3):337-8. PubMed ID: 19289778
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].
    Pédailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M
    Presse Med; 1993 Jan 2-16; 22(1):37. PubMed ID: 8469665
    [No Abstract]   [Full Text] [Related]  

  • 6. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
    de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
    Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
    Anderlini P; Sheth S; Hicks K; Ippoliti C; Giralt S; Champlin RE
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):883-4. PubMed ID: 15570257
    [No Abstract]   [Full Text] [Related]  

  • 8. [Stem cell transplantation in the imatinib era].
    Masszi T
    Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation.
    Schaich M; Schäkel K; Illmer T; Ehninger G; Bornhäuser M
    Ann Hematol; 2003 May; 82(5):303-4. PubMed ID: 12707720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated acral dermatitis due to graft-versus-host disease.
    van der Velden W; Lesterhuis J; Blokx W; Schattenberg A
    Eur J Haematol; 2009 Apr; 82(4):326. PubMed ID: 19077047
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
    Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
    Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
    [No Abstract]   [Full Text] [Related]  

  • 13. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
    Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K
    J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia.
    Ames PR; Aye WW; Beatty C; O'Reilly D
    J Rheumatol; 2008 Aug; 35(8):1682. PubMed ID: 18671330
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
    Lazar J; Poonawalla T; Teng JM
    Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
    Tolland JP; Devereux C; Jones FC; Bingham EA
    Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 19. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
    Vernon MR; Pearson L; Atallah E
    J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone marrow or peripheral blood.
    Eapen M
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):868-9. PubMed ID: 20451848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.